DSIP Clinical Trials: The Complete History
DSIP, also called emideltide, is a nonapeptide first isolated from rabbit brain in the 1970s and studied mainly by European research groups through the late 1990s. It is not FDA-approved for any use, is not an approved sleep medication, and is not a recognized treatment for pain, stress, or opioid withdrawal. Everything sold under the DSIP name today is an unapproved research or compounded product, a distinction covered in more detail in DSIP FDA status in 2026.
This page focuses on a narrower question: what did the original clinical trials actually test, what did they find, and why did that research program end rather than progress toward approval.
What was DSIP actually tested for?
The published trial record is almost entirely about one thing: chronic insomnia. Investigators gave synthetic DSIP by injection, usually in small groups of patients with established insomnia, and measured whether sleep architecture or sleep latency improved compared with placebo or baseline. A smaller strand of research looked at DSIP's effects on stress hormones (ACTH, cortisol, growth hormone, prolactin), and one later, much smaller line of work looked at opioid withdrawal and at DSIP as an anesthesia adjunct.
There was no oncology program, no chronic pain program, and no large multi-site trial. The entire clinical record is early-phase, exploratory, and small.
The trial-by-trial record
| Year | Study focus | Design (as reported) | What it found | Why it does not settle the question |
|---|---|---|---|---|
| 1981 | Sleep in insomniacs | Small trial, synthetic DSIP improves sleep in insomniacs | Reported improvement in subjective/objective sleep measures | Small sample, short duration, dated methodology |
| 1981 | Disturbed human sleep | Effects of synthetic DSIP on disturbed sleep | Some effect on sleep parameters | Same limitations; not independently replicated at scale |
| 1981 | Acute vs delayed effects | Acute and delayed effects of DSIP on sleep behavior | Distinguished immediate from lagged effects on sleep | Mechanistic interest more than a treatment answer |
| 1983 | Broader physiology | Multifunctional psychophysiological properties of DSIP | Suggested effects beyond sleep alone | Exploratory, not a defined clinical endpoint trial |
| 1984 | Insomnia | DSIP in insomnia | Mixed/modest reported benefit | Short report, limited detail on blinding and dropout |
| 1984 | Clinical trial | A clinical trial with DSIP | Similar modest findings | Same era, same scale limitations |
| 1987 | Short-term efficacy | DSIP efficacy improving sleep, short-term administration | Some short-term improvement reported | Short-term only; no data on durability |
| 1987 | 24-hour sleep-wake behavior | DSIP effects on 24-hour sleep-wake behaviour in severe chronic insomnia | Effects on sleep-wake cycle in a severe insomnia population | Severe, selected population; generalizability unclear |
| 1992 | Chronic insomniacs, double-blind | DSIP effects on sleep of chronic insomniac patients | One of the better-controlled trials in the record | Still small; the most rigorous entry in a thin body of evidence |
| 1989 | Insomnia review | Insomnia: concept and therapeutic consequences | Narrative discussion, not new trial data | Background/context only |
| 1989-1995 | Endocrine effects | Reduction of ACTH after IV DSIP, DSIP effects on AVP and ACTH, DSIP does not affect CRH/ACTH/cortisol, DSIP does not affect GH/prolactin | Findings were inconsistent across studies, some showing hormonal effects and others showing none | Small, mechanistic, not designed to answer a clinical question |
| 1998 | Opioid detoxification | Open clinical trial of DSIP in opioid detoxification | Reported some benefit in an open (unblinded) trial | Open-label design; no placebo comparison |
| 2009 | Anesthesia adjunct | DSIP alters BIS, EEG and heart rate variability with isoflurane | Physiological changes observed during anesthesia | Perioperative research context, not a sleep or standalone treatment trial |
Read across this table and a pattern emerges: the studies are consistently small, mostly from the same era, and rarely replicated by an independent group with a larger sample. The 1992 double-blind trial is the most methodologically credible entry, and even it does not approach the size or design rigor a regulator would expect to support an approval.
Did DSIP actually work for insomnia?
The honest answer is that the trials do not agree cleanly. Several report improved sleep measures; some report modest or inconsistent effects; none report a large, durable, well-replicated benefit. DSIP for sleep: what the evidence shows covers this in more depth. The endocrine studies are similarly split, with some finding DSIP altered ACTH and other hormones and others finding no such effect under different conditions. That kind of inconsistency across a small evidence base is a sign the underlying effect, if real, is modest and highly dependent on dose, timing, and population, not a sign of a robust, generalizable treatment effect.
Why did the research stop instead of scaling up?
No single trial reported a safety disaster that shut the program down. What happened instead is more mundane and more common in peptide research: a cluster of small, exploratory studies from the 1980s and 1990s never generated the kind of consistent, large-scale, well-controlled data a pharmaceutical sponsor needs to justify a phase 3 program and an FDA submission. Without a clear, replicated efficacy signal, no company had a commercial or regulatory reason to fund the much larger trials that approval would require. The opioid detoxification trial (1998) is the last entry in this specific clinical line before research on DSIP as a therapeutic largely shifted to background pharmacology and, later, unregulated research-chemical sales.
This is a different story from a drug that failed a pivotal trial. DSIP never reached a pivotal trial. The evidence base plateaued at the exploratory stage.
Does the 2026 FDA decision change this?
No, and it reinforces it. Emideltide (DSIP) has no FDA-approved application. Its FDA Category 2 nomination was withdrawn by the nominators (per the FDA Category 2 bulk substances page, content current 04/22/2026), and withdrawal is not the same as approval. DSIP is not on the 503A bulk drug substances list, and no enforcement discretion currently covers compounding it (see the FDA's 503A bulk substances framework). At its July 23-24, 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee voted against recommending emideltide for the 503A bulks list (see the meeting page). That is a regulatory rejection, not a pending or improving status. For a live view of where DSIP and related peptides stand, see the FDA Peptide Status Tracker.
What is established, what is plausible, and what is not established
Established: DSIP was tested in a number of small European trials from 1981 to 1998, mainly for insomnia, with additional work on stress hormones, opioid withdrawal, and anesthesia. Results across that body of work are inconsistent. DSIP has no FDA-approved use, and its most recent regulatory review (2026) went against it, not toward it.
Plausible but unproven: that DSIP has some measurable effect on sleep architecture or on specific stress hormones under certain conditions. The 1992 double-blind trial and several of the endocrine studies point in this direction, but the sample sizes and lack of independent replication mean this remains a hypothesis, not a demonstrated clinical effect.
Not established: that DSIP is an effective or safe treatment for insomnia, chronic stress, pain, or opioid withdrawal in general clinical use. No trial in this record was designed or powered to answer that question, and none has been repeated with modern trial standards.
Where this leaves someone considering DSIP today
Anyone weighing a compounded or research-grade DSIP product should treat the 1980s-1990s trial record as interesting background, not as proof of efficacy or safety at any particular dose. For related decisions, see DSIP mechanism of action, DSIP side effects and safety, and how DSIP compares with prescription sleep aids. If sleep difficulty is significant, worsening, or accompanied by symptoms like chest pain, severe mood change, or suicidal thoughts, that calls for urgent evaluation by a clinician rather than a peptide with an unresolved regulatory status and a thirty-year-old, unreplicated trial base.